Extracellular Vesicle-Conjugated Functional Matrix Hydrogels Prevent Senescence by Exosomal miR-3594-5p-Targeted HIPK2/p53 Pathway for Disc Regeneration
© 2023 The Authors. Small published by Wiley-VCH GmbH..
Nucleus pulposus stem cells (NPSCs) senescence plays a critical role in the progression of intervertebral disc degeneration (IDD). Stem cell-derived extracellular vesicles (EV) alleviate cellular senescence. Whereas, the underlying mechanism remains unclear. Low stability largely limited the administration of EV in vivo. RGD, an arginine-glycine-aspartic acid tripeptide, strongly binds integrins expressed on the EV membranes, allowing RGD to anchor EV and prolong their bioavailability. An RGD-complexed nucleus pulposus matrix hydrogel (RGD-DNP) is developed to enhance the therapeutic effects of small EV (sEV). RGD-DNP prolonged sEV retention in vitro and ex vivo. sEV-RGD-DNP promoted NPSCs migration, decreased the number of SA-β-gal-positive cells, alleviated cell cycle arrest, and reduced p16, p21, and p53 activation. Small RNA-seq showed that miR-3594-5p is enriched in sEV, and targets the homeodomain-interacting protein kinase 2 (HIPK2)/p53 pathway. The HIPK2 knockdown rescues the impaired therapeutic effects of sEV with downregulated miR-3594-5p. RGD-DNP conjugate with lower amounts of sEV achieved similar disc regeneration with free sEV of higher concentrations in DNP. In conclusion, sEV-RGD-DNP increases sEV bioavailability and relieves NPSCs senescence by targeting the HIPK2/p53 pathway, thereby alleviating IDD. This work achieves better regenerative effects with fewer sEV and consolidates the theoretical basis for sEV application for IDD treatment.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
---|---|
Enthalten in: |
Small (Weinheim an der Bergstrasse, Germany) - 19(2023), 37 vom: 05. Sept., Seite e2206888 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Peng, Yizhong [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.09.2023 Date Revised 29.09.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/smll.202206888 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM356686264 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM356686264 | ||
003 | DE-627 | ||
005 | 20231226071003.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/smll.202206888 |2 doi | |
028 | 5 | 2 | |a pubmed24n1188.xml |
035 | |a (DE-627)NLM356686264 | ||
035 | |a (NLM)37165721 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Peng, Yizhong |e verfasserin |4 aut | |
245 | 1 | 0 | |a Extracellular Vesicle-Conjugated Functional Matrix Hydrogels Prevent Senescence by Exosomal miR-3594-5p-Targeted HIPK2/p53 Pathway for Disc Regeneration |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.09.2023 | ||
500 | |a Date Revised 29.09.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 The Authors. Small published by Wiley-VCH GmbH. | ||
520 | |a Nucleus pulposus stem cells (NPSCs) senescence plays a critical role in the progression of intervertebral disc degeneration (IDD). Stem cell-derived extracellular vesicles (EV) alleviate cellular senescence. Whereas, the underlying mechanism remains unclear. Low stability largely limited the administration of EV in vivo. RGD, an arginine-glycine-aspartic acid tripeptide, strongly binds integrins expressed on the EV membranes, allowing RGD to anchor EV and prolong their bioavailability. An RGD-complexed nucleus pulposus matrix hydrogel (RGD-DNP) is developed to enhance the therapeutic effects of small EV (sEV). RGD-DNP prolonged sEV retention in vitro and ex vivo. sEV-RGD-DNP promoted NPSCs migration, decreased the number of SA-β-gal-positive cells, alleviated cell cycle arrest, and reduced p16, p21, and p53 activation. Small RNA-seq showed that miR-3594-5p is enriched in sEV, and targets the homeodomain-interacting protein kinase 2 (HIPK2)/p53 pathway. The HIPK2 knockdown rescues the impaired therapeutic effects of sEV with downregulated miR-3594-5p. RGD-DNP conjugate with lower amounts of sEV achieved similar disc regeneration with free sEV of higher concentrations in DNP. In conclusion, sEV-RGD-DNP increases sEV bioavailability and relieves NPSCs senescence by targeting the HIPK2/p53 pathway, thereby alleviating IDD. This work achieves better regenerative effects with fewer sEV and consolidates the theoretical basis for sEV application for IDD treatment | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a RGD | |
650 | 4 | |a extracellular vesicles | |
650 | 4 | |a intervertebral discs | |
650 | 4 | |a senescences | |
650 | 4 | |a stem cells | |
650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
650 | 7 | |a MicroRNAs |2 NLM | |
650 | 7 | |a Oligopeptides |2 NLM | |
650 | 7 | |a HIPK2 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.1.- |2 NLM | |
650 | 7 | |a Carrier Proteins |2 NLM | |
650 | 7 | |a Protein Serine-Threonine Kinases |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
700 | 1 | |a Chen, Xuanzuo |e verfasserin |4 aut | |
700 | 1 | |a Liu, Sheng |e verfasserin |4 aut | |
700 | 1 | |a Wu, Wei |e verfasserin |4 aut | |
700 | 1 | |a Shu, Hongyang |e verfasserin |4 aut | |
700 | 1 | |a Tian, Shuo |e verfasserin |4 aut | |
700 | 1 | |a Xiao, Yan |e verfasserin |4 aut | |
700 | 1 | |a Li, Kanglu |e verfasserin |4 aut | |
700 | 1 | |a Wang, BaiChuan |e verfasserin |4 aut | |
700 | 1 | |a Lin, Hui |e verfasserin |4 aut | |
700 | 1 | |a Qing, Xiangcheng |e verfasserin |4 aut | |
700 | 1 | |a Shao, Zengwu |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Small (Weinheim an der Bergstrasse, Germany) |d 2005 |g 19(2023), 37 vom: 05. Sept., Seite e2206888 |w (DE-627)NLM167400452 |x 1613-6829 |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2023 |g number:37 |g day:05 |g month:09 |g pages:e2206888 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/smll.202206888 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 19 |j 2023 |e 37 |b 05 |c 09 |h e2206888 |